Comparative Pharmacology
Head-to-head clinical analysis: NAVSTEL versus VINCASAR PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAVSTEL versus VINCASAR PFS.
NAVSTEL vs VINCASAR PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NAVSTEL is a vascular disrupting agent that selectively targets and disrupts tumor vasculature by binding to tubulin at the colchicine-binding site, leading to microtubule depolymerization, cytoskeletal disruption, and subsequent endothelial cell apoptosis and necrosis in tumors.
Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation and disrupting mitotic spindle assembly, thereby arresting cell division in metaphase.
400 mg orally once daily
1.4 mg/m2 intravenously once weekly, typically not exceeding 2 mg.
None Documented
None Documented
Terminal half-life is 12 hours (range 10–14 h). With normal renal function, steady-state is reached after 2–3 days. Half-life extends to 24 hours in moderate renal impairment.
Terminal elimination half-life ranges from 24 to 35 hours in adults, with a mean of approximately 25 hours. The half-life may be prolonged in patients with hepatic impairment.
Renal excretion of unchanged drug accounts for 70% of clearance; biliary/fecal elimination accounts for 25%; 5% metabolized.
Primarily hepatobiliary excretion; approximately 80% of the dose is eliminated in feces, with less than 20% excreted unchanged in urine. Renal clearance is minor.
Category C
Category C
Vinca Alkaloid Antineoplastic
Vinca Alkaloid Antineoplastic